Targeting Cancer Cells with Smart, Internalizing Antibodies
This patent describes a special antibody with two binding parts, one that finds a cancer target and another that helps the whole molecule get pulled inside the cancer cell more effectively, especially when the target is present.
Patent Number
US 20230076417
Status
Active
Filing Date
April 6, 2022
Grant Date
—
Expiration
April 6, 2042
Claims
55
Assignee
Genmab AS
Inventors
Joost MELIS, Tom Vink, Esther BREIJ, Paul Parren, Bart De Goeij, Hendrik TEN NAPEL, David Satijn
Citations
1 forward · 1 backward
What it covers
This patent describes a special molecule, like an antibody, that has two specific parts, called antigen-binding domains. The first part is designed to attach to a 'target molecule (T)' often found on cancer cells (Claim 1). The second part attaches to an 'internalizing effector protein (E)' (Claim 1), which is a protein on the cell surface that helps pull things inside. The key feature is that this second part has a very specific binding strength, or 'dissociation constant (KD),' for the effector protein (E), set between 10^-9 and 10^-8 M (Claim 1). This precise binding strength helps the entire molecule get pulled into the cell more efficiently, especially when the target molecule (T) is also present (Claim 8, 10). For example, a HER2xCD63 bispecific antibody (Claim 36) could be designed to deliver a drug inside HER2-positive cancer cells.
What it doesn't cover
- —Antibodies that only bind to one target (monospecific antibodies), as it requires a 'first antigen-binding domain and a second antigen-binding domain' (Claim 1).
- —Multispecific antibodies where the second binding domain's affinity (KD) for the internalizing effector protein (E) is outside the specified 10^-9 to 10^-8 M range (Claim 1).
- —Molecules that internalize into cells without requiring the presence of the target molecule (T) for enhanced internalization (Claim 8).
- —Molecules where the effector protein (E) is not a cell surface molecule that is internalized into the cell (Claim 7).
- —Molecules where the target (T) is not associated with a tumor or cancer (Abstract, Claim 35).
The clever bit
The clever part is precisely defining the optimal binding strength (dissociation constant) for the second antigen-binding domain to an internalizing effector protein. This specific affinity range (10^-9 to 10^-8 M) is crucial for ensuring the molecule not only binds to the cell but also gets efficiently pulled inside and transported to the lysosomal compartment, especially when the cancer target is present (Claim 1, 10). This fine-tuning enhances targeted delivery.
Why it matters
This technology aims to improve how therapeutic molecules, like drugs, are delivered into cancer cells. Many effective cancer treatments need to get inside the cell to work properly. By making the delivery process more efficient and specific to cancer cells, this approach could lead to more potent treatments with fewer side effects, potentially improving patient outcomes.
Real-world examples
- 1.Antibody-drug conjugates (ADCs) for cancer treatment
- 2.Bispecific antibodies designed to deliver drugs into tumor cells
- 3.HER2-targeting therapies that require cellular uptake
- 4.CD63-targeting therapies for enhanced internalization
Generated by PatentBrief · Not legal advice · patentbrief.org
US 20230076417 · 2026